Newsletter Tool

To view this email as a web page, click here

Today's Rundown

Eli Lilly's COVID-19 antibody sales crater as variants, vaccines take a toll
Alnylam scraps COVID-19 antiviral citing effective vaccines, alternative treatments
Kaiser Permanente requiring all 240K employees, physicians to be fully vaccinated against COVID-19
CytoDyn catches SEC, DOJ scrutiny over public claims about COVID-19 drug's viability
With $3.2B, Sanofi takes in mRNA partner Translate Bio in buyout deal
UPDATED Coronavirus tracker: Health policy expert calls for wider use of N95s, simpler masking recommendations
COVID-19 tracker: U.S. donates over 110M doses so far; Alnylam, Vir ditch antiviral due to vaccines, other drugs

Featured Story

Eli Lilly's COVID-19 antibody sales crater as variants, vaccines take a toll

By Noah Higgins-Dunn

Eli Lilly's COVID-19 antibody sales plummeted as virus variants and greater vaccine access weighed on the company's pandemic prospects.

Alnylam scraps COVID-19 antiviral citing effective vaccines, alternative treatments

By Kyle LaHucik

The pharma said it was ending ALN-COV, its RNAi antiviral being developed for the treatment of SARS-CoV-2, because of the number of effective vaccines and alternative treatments available. Alnylam and partner Vir Biotechnology had said they would start testing patients by the end of last year.

Kaiser Permanente requiring all 240K employees, physicians to be fully vaccinated against COVID-19

By Dave Muoio

With its Sept. 30 cutoff, Kaiser Permanente is now the largest health system to mandate a COVID-19 vaccine among employees.

CytoDyn catches SEC, DOJ scrutiny over public claims about COVID-19 drug's viability

By Annalee Armstrong

The blows keep coming for CytoDyn. After the FDA blasted the company for pumping up their unapproved and unproven COVID-19 therapeutic, the Department of Justice and the Securities and Exchange Commission is now subpoenaing the company and its executives. Two investigations were disclosed in an SEC filing dated July 30.

With $3.2B, Sanofi takes in mRNA partner Translate Bio in buyout deal

By Nick Paul Taylor

After being left out of the COVID-19 vaccine race despite having an early investment in mRNA technology, which would go on to give the world two vaccines in record-breaking time, Sanofi has struck a deal to buy its mRNA partner Translate Bio in a $3.2 billion deal.

UPDATED Coronavirus tracker: Health policy expert calls for wider use of N95s, simpler masking recommendations

By Healthcare Staff

Follow along with the latest COVID-19 news straight from the Fierce Healthcare team.

COVID-19 tracker: U.S. donates over 110M doses so far; Alnylam, Vir ditch antiviral due to vaccines, other drugs

By Noah Higgins-Dunn,Kevin Dunleavy,Fraiser Kansteiner

The U.S. has donated over 110 million vaccine doses to more than 60 countries, and the Biden administration said that's just the start. Alnylam and Vir Biotechnology are ditching their COVID-19 antiviral, citing the availability of highly effective vaccines and alternative treatments. And more headlines.

COVID-19 Tracker